Global vaccine market 2008 profiles _ Jiang Guang strategy

(Continued from text) children's vaccine market due to the lack of enough vaccine to control infectious diseases, poor pay tremendous minors death and disability. According to who statistics, infectious disease caused by the death of total deaths, 1/3 of at least 15 million people. With more than 500 million is aged less than 5 years old children. Of these, estimated to be at least 200 million from existing vaccines effective control. Despite the slow global immunization rate is steadily increasing. But significant regional differences. 2006 global about 3000 million infants no vaccination with DPT3, of which 75% live in China, India, Nigeria, Indonesia, Pakistan, Sudan and other regions. Coverage rate of over 90% of countries have 114, accounting for 59% of the global scope. In 2004 and 2005 respectively, this data is 100 and 112. Products----BCG: BCG is used for the prevention of tuberculosis infection vaccine. For the long-term and high risk for TB patients in contact with the infant immunization, vaccination before do skin allergy testing. Worldwide there are many brands of BCG and common names of BCG, leading brands including the Organon company (October 2007, the acquisition by Schering-Plough) Tice BCG and Otunnu Mycobax of non-Pasteur. -Diphtheria, tetanus, pertussis, polio vaccine, hepatitis b and 2002 FDA approval of Glaxo's Pediarix vaccine history, this is the first listing of five vaccines. Usually the first two years after the birth of infants need injection 24-pin, so an override 1053 mother of 90 per cent of respondents want compound vaccine. ----Haemophilus influenzae type b vaccine: Haemophilus influenzae is the caused infant meningitis and bacterial pneumonia. This type of vaccine effectiveness significantly, side effects, major manufacturers including Glaxo history (Hiberix), Merck (PedvaxHIB), Novartis (Quattvaxem, Vaxem-HIB), Otunnu non-Pasteur (Act-HIB) and Whitworth (HibTITER). -Hepatitis a vaccine: hepatitis a through person-to-person spread of iatrogenic way. Children adult hepatitis a gentler, more dangerous. The incidence and severity of the social and economic development, it is estimated that each year there are 150 million patients worldwide. Vaccine leading products include Havrix (Glaxo history), Vaqta (Merck) and Avaxim (Otunnu non-Pasteur). Glaxo history of Twinrix is the second of hepatitis b vaccine. ----The measles, mumps and rubella vaccine: vaccine against this class of 40 years of history, usually a triple MMR vaccine, known as. A well-known brand M-M-R Ⅱ andProQuad (Merck), Trimovax and r.o.r. (Otunnu non-Pasteur), LM-3 RIT (Korea Dong ShinPharm) and Priorix (Glaxo history). -Pneumococcal conjugate vaccines: pneumococcal and Streptococcus pneumoniae is an important cause of serious infections, often causing pneumonia bacteria, bacteremia, sinusitis and acute otitis media. Although the age can be infected, but the incidence of children and the elderly. WHO statistics each year there are 120 million children die from pneumococcal infection. In 2000, the United States FDA approved Whitworth Prevnar Pneumococcal conjugate vaccine, now has nearly 50 ratifications. 2008 European food and Drug Administration (EMEA) accept Glaxo history for Synflorix review applications. ----Rotavirus vaccine: Rotavirus infection is the 3-24-month-old infants with severe diarrhoea and vomiting main pathogenic factors. Each year approximately 1.38 million infants infected with rotavirus causes diarrhea, diarrhea etiology of 40%, resulting in 60 000 deaths. More than 85% of cases have occurred in the "low income". 2004 July Rotarix (Glaxo history/Ann completion) for Mexico drugs approved by the management for the prevention of rotavirus infection causes of gastroenteritis, subsequently approved in Europe. In February 2008 was approved in the United States. Merck's RotaTeq2006, get the United States FDA approval. The third approved vaccines are China, Lanzhou Institute of biological products and IVI cooperative development of sheep attenuated vaccines, monoclonal antibodies, and only the Chinese approval numbers--chickenpox varicella vaccine: is zoster virus causes an acute, highly contagious disease. Children, adult onset of moderate and more serious. Varicella vaccine 1974 listing, zoster virus inactivation of Oka strain. Merck and Glaxo history of the brand are Varivax and Varilrix. ----Meningococcal vaccine: meningococcal meningitis caused by a relatively rare bacterial pathogens. Bacteria or virus from other parts of the body's infection lesions with blood flow to the brain causes meningitis infection mater. In March 2007, Glaxo history which can be obtained from the European Drug Administration submitted a combined vaccine Globorix applications, the vaccines against diphtheria, pertussis, tetanus, hepatitis b, Haemophilus influenzae type b and meningococcal A and C. The children's vaccine 2008 estimated 200 children vaccines at the various stages of development. Dengue fever: WHO estimated 25 million people are at risk of being infected, including 10 million children. Each year more than 1 million clinical cases of dengue fever and dengue hemorrhagic fever and 50 million shock symptoms, leading to half a million deaths. In 2006, a group of scientists in Argentina found that dengue virus replication mechanism, Glaxo history and WalterReed Academy of military sciences jointly developed the first vaccine. Thailand's Mahidol University and collaboration with non-Pasteur Otunnu developed a second vaccine clinical trials show a second injection of the vaccine can be three times on the four dengue virus subtype. Otunnu non-Pasteur also separately and children against the disease Foundation and Acambis cooperative development such vaccines. Enterotoxigenic enteropathic bacteria: each year, around 2 million infections and cause 40 000 deaths. An out-There is currently one against enterotoxigenic enteropathic bacteria and cholera vaccines in early testing phase. Cambridge University and ACE biotechnology also in research and development for the germs of oral vaccine. Influenza: Although the flu vaccine is also used for adult immunization, but also researchers in developing vaccines for children. Parainfluenza virus III: parainfluenza virus III is a paramyxovirus family 4 single-stranded RNA virus subtype. Is located in the respiratory syncytial virus cause upper respiratory infections of major pathogens. United States allergy and infectious diseases Association has created a three-type virus internal proteins and a virus surface glycoprotein and red blood cells lectin neuraminidase of attenuated live vaccines. MedImmune also developed a second vaccine. Pneumococcal vaccine: vaccine 7 Whitworth Prevnar is 7 different subtypes of pneumococcal vaccines, but on some of the in Streptococcus pneumoniae is invalid. There is now targeted at 13 subtypes of 13 price version of Prevnar listing. 2007 year-end Glaxo history may also submit to the European Union 10 price of pneumococcal vaccine, known as Streptorix. Respiratory syncytial virus: the virus causing infants and children with lower respiratory tract serious infection. According to estimates, the infection rate and mortality 6400 million respectively and 16 000. MedImmune1998 year listing of Synagis is against the virus of monoclonal antibodies and become a standard treatment. But Synagis does not belong to the vaccine. In 2006, AkzoNobel's Nobilon and Norway Vaccine Institute signed a cooperation agreement to develop a vaccine against the virus. Development of non-Pasteur Otunnu's sub-unit vaccine is also at the stage of clinical phase II trials. Shigella dysenteriae: bacillary dysentery global annual incidence 1.647 million cases, of which 1.632 million patients in developing countries, 150 million patients in developed countries. WHO estimates that each year more than 110 million people died of infection, of which 58 000 patients are the industrialized countries of the traveler (tourism, travel, immigration, etc.). In the episode ' lethality by 69%, 61% in less than five years old. An end own a preclinical research stage is in the vaccines in development. NIH's combined vaccine is in phase II clinical stage. Global children's vaccine market-market capacity and forecast 2007 global children's vaccine sales over US $ 8 billion, representing 63 billion in 2006 25.2%. So high speed growth, partly because the pneumococcal vaccine Whitworth Prevnar and Merck's RotaTeq rotavirus vaccines on the market. According to the forecast, 2007 to 2012 Prevnar sales will moderate growth. Total vaccine market 2008 to 2013 in annual average growth rate forecast 14.2% 2013 to 188 million. In 2007, the pneumococcal vaccine is the largest market share of children vaccines, occupy 33.5% of total sales. It is expected that due to the growth of other types of vaccines, 2013 this value will drop to 29.1%. Combined vaccine will occupy the second position, from the 2007 11.6% to 2013 11.7%. Other types of vaccines, including rotavirus vaccines, influenza virus vaccine and Escherichia coli in occupies the third place, 2007 total revenues since 10.4% expected new listing 2013 share increased to 21.7%. ----DPT triple vaccine market 2007 DPT DPT total sales of 5 billion, in 2006, approximately $ 4.82 million. It is expected that such vaccines for 2008 to 2013 as 3.8% CAGR, 2013 6.3 billion. The data means that 2004-2013 annual compound growth rate of 4.2%. 2007 DPT DPT3 vaccine market in occupies the children 6.8%. It is expected that as the pneumococcal vaccine and other compound vaccine's rapid growth, the proportion dropped to 2013 3.3%. 2007 global hepatitis vaccine market about 7.9 billion in 2006, approximately $ 6.65 million. 2004-2008 such vaccines ~ 17.1%. 2013 Annual Conference is expected to reach $ 19, 2004-2013 of the compound growth rate of 15.7%. In 2007, hepatitis a vaccine to occupy the vaccine market 10.7% share, to 2013 may drop to 10.4% expected DPT triple vaccine sales growth because more compound vaccine appears while the slowdown. Such as Glaxo history of Infanrix contains the DPT vaccine, also has a preventive polio, hepatitis b and Haemophilus influenza viruses. The product listing in 2003 and quickly gain market recognition. Children DPT vaccine market leader remains Glaxo history. Infanrix Pediatrix 2007 and achieved sales of $ 10.77 6.2% year-over-year growth. Infanrix's main competitors are Otunnu non-Pasteur's DPT DPT. Glaxo history may have DPT DPT Boostrix, 2007 sales of $ 1.3. The vaccine is mainly local producers in various parts of the production. -----Hepatitis vaccine market generally hepatitis b vaccination in infants is recognized control effective means of HBV transmission. At birth and before hospital discharge, respectively of the injection and baby can only accept monovalent hepatitis b vaccine. Therefore neonatal hepatitis b vaccine market will continue to grow steadily. But as with hepatitis b vaccine features combined vaccine, for 1-year-old and above-market sales of monovalent vaccines will be gradually reduced. Market's largest four hepatitis b vaccine are Engerix-B (Glaxo history), Recombivax (Merck) and Biken-HB (Japan Institute of Microbiology), as well as GenHevacB (arseno-Pasteur). Leading a Havrix hepatitis a vaccine (Glaxo history), Vaqta (Merck) and Avaxim (arseno-Pasteur). Glaxo history of hepatitis b is a Twinrx DPT vaccine, for 1-15-year-old crowd. ----Haemophilus rodStrain vaccine, Haemophilus influenzae type b vaccine market by 2006 2.45 6.1 percent to $ 2.6 million in 2007. Projected 2008-2013 5.3% CAGR, 2013 sales 3.56 billion. In 2007, the total child class vaccine vaccine market, it is expected that 3.5% 2013 Annual Conference to 1.9%. And hepatitis and tetanus vaccines, influenza b also to compound vaccine development. Monovalent hepatitis b vaccine market is expected to slow growth. But because the price is cheaper than the combined vaccine, the coming decades monovalent vaccines in developing countries will have a huge space for development. The Whitworth HibTITER, Otunnu's non-Pasteur and Merck of PedvaxHIB Act-HIB is the market leader and major competitors. ----The measles, mumps and rubella vaccine 2007 measles, mumps and rubella vaccine sales 7.4 million the previous year's $ 6.05 22.3%. Projected 2008-2013 CAGR 11.6% 2013 sales reach 14 million. This triple vaccine covers 2007 children's vaccine market 10.1%, it is expected that the proportion dropped to 2013 8%. 2007 leading two brands is Merck's M-M-R Ⅱ and Otunnu non-Pasteur's Trimovax. In September 2005 the FDA approved the Merck vaccine ProQuad tetravalent, against measles, mumps, rubella and varicella. But because the price is too high and distribution system, sales have been poor. And 2008 United States Centers for disease control and prevention released report shows and traditional trivalent vaccine plus varicella vaccine compared to the price of vaccine-induced fever and cramps cases more efficient. 2007 Merck Announce ProQuad, M-M-R Ⅱ and Varivax Wal-Mart achieved global sales of $ 13 billion in 2006, this data is 8.2 billion. --Compound vaccine market 2007 combined vaccine market sales from 2006 7.2 18.1 percent to 8.5 billion. 2013 Annual Conference is expected to reach $ 22, 2008-2013 of the compound annual growth rate of 17.7%. 2007 combined vaccine covers child vaccine market 11.6% 2013 Annual Conference is expected to increase to 12%. Compound vaccine is a single product contains lead to several different disease pathogens of Antigen or the same diseases caused by pathogens of multiple subtypes. The current compound vaccine up to 7 vaccines can be prevented diphtheria, tetanus, pertussis, polio, hepatitis b, varicella and Haemophilus influenza viruses. In industrialized countries, the compound vaccine because of its reduced injection times and reduce overall costs and outstanding performance. The current United States children's immunization program in the 2-year-old former needs about 25 vaccine inoculation, along with the new product has introduced this number will increase. Compound vaccine helps reduce injection times and cost savings. Although the compound vaccine prices may be higher than the sum of the price of monovalent vaccine, but if you consider appropriate injection and other direct and indirect costs still has economic advantages. But in developing countries because of the price due to the limited space of compound vaccine unless prices. WHO anticipates that this process will take at least 10 years. Xu is the manufacturer provides a combined vaccine. Glaxo history of Pediarix2002 years listing, was the first to receive FDA approval of pentavalent vaccine compound. 2007 sales (together with Infanrix) year-on-year growth rate of 6.2% to $ 10.77 billion. Addition of non-Pasteur Otunnu Daptacel, Pediacel and Pentavac are compound vaccine leader. Industry inner constantly developing new composite vaccine products. For example, the 2006 Korea food and Drug Administration approved the world's first liquid of pentavalent vaccine Crucell's Quinvaxem (diphtheria, pertussis, tetanus, hepatitis b and Haemophilus influenzae type b). -Pneumococcal vaccine against pneumococcal vaccine in 2007 compared with the big 30.9%, from 06-year 19 million increase to 24 billion. It is expected that due to the Whitworth Prevnar and new product constantly promoted, 2013 sales of up to 56 million. Such vaccines 2007 accounted for child vaccine market 33.5%, the proportion is expected to 2013 to 29.8%. Like Merck's Pneumovax 23 such a polyvalent polysaccharide vaccine (PPV) listed several years ago, but unable to stimulate the most high-risk infants and children immune response. In 2000, the FDA approved the Whitworth improved 7 price polysaccharide vaccine (PCV) Prevnar, this product is also applicable to children. The most common 7 strains of pneumococcal immunization effect there. Prevnar listing appeared well blowout sale. In fact in 2002 due to the production and supply chain of sales to Prevnar has limitations. 2006 launch of premix Whitworth Prevnar injection needles. Prevnar constitute 2007 pneumococcal vaccine market's major components. According to data released by the company Whitworth, Prevnar2005, 2006 and 2007 sales were $ 15.1, 19.6 billion and 24.4 billion. Whitworth won the United States due to the national immunization programme and additional orders and other market launch of the product, so the next few years it is expected that sales will grow. But Prevnar for developing popular strains no preventive effect, so the market is limited to industrialized countries. The soon-to-be-launched new products will drive sales growth. Whitworth is expected to soon launch price of Prevnar 13. Glaxo history to the end of 2007 to the European Medicines Authority submitted 10 Streptorix vaccine products. Although the new product will compress Prevnar of space, but the overall market will continue to expand, especially in markets outside United States. ----Polio vaccine, polio vaccine sales for 2007 is 4.82 billion, compared to the 2006 4.288 IMEX$ 12.4 percent. 2004-2008 ~ 12.5% 2013 sales expected to reach $ 1 billion. Polio vaccine covers 2007, the children's vaccine market, it is expected that 6.6% 2013 Annual Conference to 5.4%. Since the 1960s discovered polio immunization, disease almost take the vaccine to all areas of eradication. However there are still about 20% in high-risk groups, no polio vaccine. At present there are two major types of oral polio vaccine: live virus vaccine (OPV) and fire injections of vaccine. The largest product sales is the non-Pasteur Otunnu IPOL and IPV. ----Varicella vaccine 2007 varicella vaccine market is 5.05 billion, compared to the 2006 4.15 21.7 percent. 2004-2008-year compound annual growth rate of about 19% is expected for 2004-2013 15.6% CAGR until 2013 annual sales of up to 13 million. Varicella vaccine covers child vaccine market 6.9%. It is expected that this proportion will be on that level. September 2004 edition of the journal of Pediatrics article reports that due to the severe varicella vaccine application allows to reduce the number of cases each year for the United States health care system to save 1 million of expenditure. It is worth noting that the chickenpox vaccine and measles, mumps, and rubella vaccine, also for the adult market, particularly in high-risk populations, such as health care workers. But there is no valid on adult market. With Merck's application of compound vaccine ProQuad, as well as an up-Pasteur and Glaxo history to cooperation and development in the third stage clinical vaccine market, single varicella vaccine in developed countries there will be a slight decline in sales, but due to the developing market growth over the next five years and varicella vaccine overall market will remain at 3.6%. The world's largest two varicella vaccine brand is Varilrix (Glaxo history) and Varivax (Merck). Varivax is the only permitted in the United States vaccines. In addition there are many throughout the world and local producers. Merck reports 2007 its ProQuad, M-M-R Ⅱ and Varivax total sales 13 billion, the 2006 sales 8.2 billion. ----Other vaccine market other vaccines include influenza, diphtheria, tetanus, rotavirus, enterotoxigenic enteropathic bacterium, Bacillus Calmette-Guerin, Japan encephalitis, yellow fever, rabies and vaccines. In 2007, these vaccine sales of almost 14 billion, compared with the previous year has doubled. Mainly because Merck's RotaTeq, a new product and Glaxo history listing of Rotarix, both against Rotavirus infection. 2004-2008 class of vaccine ~ 40.9%. Expected 2013 $ 41 billion. Other vaccine covers the entire 2007 children's vaccine market 10.5%. It is expected that in 2003, this proportion rises to 22.2%. These vaccines are for different diseases and pathogens. As people on the efficacy of the vaccine, population growth and new products to market, the demand for these vaccines are growing. BCG's leadership brand is the Organon of Tice. Novartis's Encepur is tick borne encephalitis vaccine leading brand. GreenCross manufacturing and sale of non-Pasteur Otunnu JE-VAX is leading the vaccine of Japan. Otunnu non-Pasteur's VeroRab and Novartis's RabAvert is rabies vaccine brand. Otunnu non-Pasteur's YE-Vax is the best-selling yellow fever vaccine. Otunnu non-Pasteur also offers several leading influenza vaccine. Merck rotavirus vaccine RotaTeq2007 annual sales of $ 5.25, Glaxo history of Rotarix to 2 billion. These two products will gradually for babies and children. (To be continued) (Note: this article was published on November 2009)